| Literature DB >> 35682904 |
Zehui Li1, Aiping Wang1, Jingming Zhou1, Yumei Chen1, Hongliang Liu1, Yankai Liu1, Ying Zhang1, Peiyang Ding1, Xifang Zhu1, Chao Liang1, Yanhua Qi1, Enping Liu1, Gaiping Zhang1,2,3.
Abstract
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the pathogenic agent leading to COVID-19. Due to high speed of transmission and mutation rates, universal diagnosis and appropriate prevention are still urgently needed. The nucleocapsid protein of SARS-CoV-2 is considered more conserved than spike proteins and is abundant during the virus' life cycle, making it suitable for diagnostic applications. Here, we designed and developed a fluorescent immunochromatography assay (FICA) for the rapid detection of SARS-CoV-2-specific antibodies using ZnCdSe/ZnS QDs-conjugated nucleocapsid (N) proteins as probes. The nucleocapsid protein was expressed in E.coli and purified via Ni-NTA affinity chromatography with considerable concentration (0.762 mg/mL) and a purity of more than 90%, which could bind to specific antibodies and the complex could be captured by Staphylococcal protein A (SPA) with fluorescence displayed. After the optimization of coupling and detecting conditions, the limit of detection was determined to be 1:1.024 × 105 with an IgG concentration of 48.84 ng/mL with good specificity shown to antibodies against other zoonotic coronaviruses and respiratory infection-related viruses (n = 5). The universal fluorescent immunochromatography assay simplified operation processes in one step, which could be used for the point of care detection of SARS-CoV-2-specific antibodies. Moreover, it was also considered as an efficient tool for the serological screening of potential susceptible animals and for monitoring the expansion of virus host ranges.Entities:
Keywords: SARS-CoV-2; fluorescent immunochromatography assay; nucleocapsid protein; point-of-care detection; quantum dots
Mesh:
Substances:
Year: 2022 PMID: 35682904 PMCID: PMC9180975 DOI: 10.3390/ijms23116225
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Figure 1Identification of purified nucleocapsid protein and QDs-conjugated N protein. (a) Purified nucleocapsid protein isolated by 12% SDS-PAGE. (b) Purified nucleocapsid protein isolated by Western blot. Lane 1: Protein Ladder. Lane 2: N protein reacted with anti-His-Tag mouse monoclonal antibody (5C3). (c) QDs and conjugates identified by agarose gel electrophoresis. (d) Fluorescence spectrum of QDs and conjugates. (e–h) Size distribution and ζ potential distribution of QDs and conjugates, as measured by Malvern Zetasizer.
Optimization of conjugating conditions of QDs-N probe by using orthogonal tests.
| Group | The Ratio of EDC | The Ratio of N Protein | pH of PBS | FI of Test Line |
|---|---|---|---|---|
| 1 | 1:1500 | 1:2.5 | 7.4 | 1372 ± 24 |
| 2 | 1:2000 | 1:2.5 | 8.0 | 11,109 ± 22 |
| 3 | 1:2500 | 1:2.5 | 6.8 | 2368 ± 4 |
| 4 | 1:2500 | 1:5.0 | 7.4 | 3551 ± 10 |
| 5 | 1:1500 | 1:5.0 | 8.0 | 7375 ± 3 |
| 6 | 1:2000 | 1:5.0 | 6.8 | 6050 ± 4 |
| 7 | 1:2000 | 1:7.5 | 7.4 | 6145 ± 8 |
| 8 | 1:2500 | 1:7.5 | 8.0 | 24,797 ± 5 |
| 9 | 1:1500 | 1:7.5 | 6.8 | 16,817 ± 14 |
Figure 2Optimization of conjugating conditions of QDs-N probes. (a) Fluorescent intensity of 9 probes synthesized with different conditions tested by fluoro-immunoassay. (b) Fluorescent Spectrum of 9 probes, which indicated that the conjugation 8 presented the best fluorescent performance.
Figure 3Schematic illustration of the lateral flow assay for the rapid detection of antibodies against SARS-CoV-2 N protein. (a) Schematic diagram of the detection device. (b) Interpretation of different testing results under UV light. “C” and “T” refer to the control line and the test line, respectively.
Figure 4Optimization of coating concentrations, pH and buffer solution of the lateral flow assay. (a,b) Optimization of coated mAbs and SPA on the T line and the C line. The fluorescent intensity data was presented by heat map. (c,d) Optimization of the dilution buffer and pH. (e–g) Optimization of reaction time by testing mAbs, antiserum and negative control.
Figure 5The limit of detection and cross-reactivity of the lateral flow assay. (a,b) The limit of detection of the lateral flow assay. (c,d) Cross-reactivity with other coronaviruses and respiratory-infection-related viruses (n = 5).